157 related articles for article (PubMed ID: 7517668)
21. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.
Goldman ME; O'Brien JA; Ruffing TL; Schleif WA; Sardana VV; Byrnes VW; Condra JH; Hoffman JM; Emini EA
Antimicrob Agents Chemother; 1993 May; 37(5):947-9. PubMed ID: 7685996
[TBL] [Abstract][Full Text] [Related]
22. Mutagenesis of the Glu-89 residue in human immunodeficiency virus type 1 (HIV-1) and HIV-2 reverse transcriptases: effects on nucleoside analog resistance.
Song Q; Yang G; Goff SP; Prasad VR
J Virol; 1992 Dec; 66(12):7568-71. PubMed ID: 1279207
[TBL] [Abstract][Full Text] [Related]
23. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
[TBL] [Abstract][Full Text] [Related]
24. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
[TBL] [Abstract][Full Text] [Related]
26. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
27. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
28. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
29. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
30. 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
Lobatón E; Velázquez S; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):711-4. PubMed ID: 11563098
[TBL] [Abstract][Full Text] [Related]
31. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
[TBL] [Abstract][Full Text] [Related]
33. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
34. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
35. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Maass G; Immendoerfer U; Koenig B; Leser U; Mueller B; Goody R; Pfaff E
Antimicrob Agents Chemother; 1993 Dec; 37(12):2612-7. PubMed ID: 7509144
[TBL] [Abstract][Full Text] [Related]
36. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
38. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.
Balzarini J; Brouwer WG; Felauer EE; De Clercq E; Karlsson A
Antiviral Res; 1995 Jun; 27(3):219-36. PubMed ID: 8540745
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
Buckheit RW; Kinjerski TL; Fliakas-Boltz V; Russell JD; Stup TL; Pallansch LA; Brouwer WG; Dao DC; Harrison WA; Schultz RJ
Antimicrob Agents Chemother; 1995 Dec; 39(12):2718-27. PubMed ID: 8593008
[TBL] [Abstract][Full Text] [Related]
40. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase.
Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):947-9. PubMed ID: 14565318
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
